The Study
Abstract A068: Preclinical investigation of orally bioavailable, potent pan-KRAS (ON/OFF) inhibitor JAB-23E73
This study tested a new medicine in test tubes and mice, not people. It shows the medicine can stick to a cancer protein and shrink tumors in mice, but that doesn't mean it will work in humans.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made a new pill that stops a broken protein (KRAS) that makes many cancers grow, even when other drugs don't work.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — it works on many KRAS mutations that currently have no good drugs, and it works by mouth with no major side effects seen in mice.
- 2The pill binds tightly to KRAS mutants (better than 1 billionth of a gram per liter), blocks cancer signals at nanomolar levels, and shrinks tumors in mice with KRAS mutations.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Molecular Cancer Therapeutics
Year
2025
Authors
Peng Wang, Xiaoyu Liu, Wei Zhang, Dan Liu, Xueting He, Cunbo Ma, Amin Li, Yiwei Lin, Xin Sun, Wei Long, Yanping Wang
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.